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ABSTR ACT: Benign mammary lumps and mastalgia are the most common breast disorders; yet, there is no clear-cut consensus about the best strategy for 
their treatment. We hypothesized that a combination, including boswellic acid, betaine, and myoinositol, would be beneficial in breast disorders by exerting 
a pleiotropic effect on multiple pathways. Indeed, myoinositol has already been proven to modulate some factors involved in the genesis of breast diseases, 
such as fibrosis and metabolic and endocrine cues. In our study, 76 women were randomly assigned to either the experimental or the placebo arm. After six 
months of treatment, statistically significant differences between the two groups were recorded for pain relief (56% vs 17%) and breast density reduction 
(60% vs 9%). Furthermore, benign breast mass dimension showed a reduction in the experimental group (40% vs 16%). The combination of boswellic acid, 
betaine, and myoinositol has been demonstrated to be effective in the treatment of breast pain and radiologically and histologically confirmed benign breast 
mass and in the reduction of breast density, one of the pivotal risk factors for the development of breast cancer, without any side effects.
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Introduction
Breast pain (mastalgia) is a very common disorder experienced 
by women, and it was recognized as a relevant medical issue 
even before its first description, reported in the scientific 
literature in 1829.1,2 Pain is usually associated with mam-
mary masses, and it represents a major symptom belonging 
to benign breast disorders. Clinical surveys have estimated 
the occurrence of breast ache, from mild discomfort to severe 
pain, at 60%–80% in women, and the real prevalence is likely 
to be higher, given that fewer than half of women with severe 
pain are willing to report this symptom to a physician.3 Breast 
pain may be severe enough to interfere with usual daily activi-
ties, and its effects on the quality of life as well as its psycho-
logical implications are often underestimated.4
Mastalgia is usually thought to be inextricably linked to 
fibrocystic disease, as reported in many textbooks, and breast 
pain is generally deemed to be a dysfunctional consequence 
of the benign dysplasia. Undeniably, benign breast diseases 
(BBDs) are frequently associated with breast pain or dis-
comfort. However, the association between breast pain and 
fibrocystic histology is far from consistent, given that the same 
incidence of a wide array of fibrocystic histological findings 
has been reported in women with or without breast pain.5,6
There are three main clinical categories of breast pain: 
cyclic mastalgia (arising during the luteal phase of the cycle), 
noncyclic mastalgia, and extramammary pain (musculoskele-
tal tenderness or pain associated with breast discomfort and/or 
benign lumps).7 The odds of treatment success may vary 
according to the different types of pain.8
Current available therapies are inadequate and a search for 
an optimal strategy is still warranted. In some cases, pain relief 
can be obtained even without pharmacological intervention by 
means of psychological care, while in some instances medi-
cations are effective.9 Promising results have been obtained 
with evening primrose oil,8 although a subsequent random-
ized, multicentric study does not support previous reports.10 
In some studies, about two-thirds of patients with noncyclic 
breast pain or associated musculoskeletal ache responded to 
oral or topical anti-inflammatory, nonsteroidal treatment,11,12 
evidencing how important inflammatory processes could be in 
the emergence of BBDs. Consistent results have been obtained 
with a few endocrine manipulations, but the concomitant side 
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effects led a relevant fraction of patients to discontinue the 
drugs. Danazol, tamoxifen, gonadotropin-releasing hormone 
agonist, and bromocriptine are usually recognized to be effec-
tive in selected groups,13–16 but ultimately, the large number 
of hormonal approaches and remedies promoted to alleviate 
mastalgia attests the lack of a single effective agent with ew 
adverse effects.17 Moreover, various approaches highlight our 
limited understanding of the complexity of BBDs.
Actually, mastalgia is still an enigmatic condition, as its 
causes are poorly understood and are likely to be multifactorial. 
Molecular alterations typical of malignant breast carcinomas 
do not seem to occur in benign breast lesions.18 Hormonal 
imbalances,19 metabolic and inflammatory processes,18 and 
disorders of the crosstalk among epithelial cells and the 
surrounding stroma are deemed to have roles in the etiology 
of benign breast pain, as evidenced by the increased rate of 
mastalgia in women with simple duct ectasia.20,21 Moreover, 
while no relevant changes in circulating steroid sex hormones 
have been related in women with BBDs,22 it has been sug-
gested that hormonal disorders play a part in the genesis of 
mastalgia. Indeed, breast pain arises in a relevant fraction of 
women undergoing endocrine, estrogen-based treatments. 
Moreover, mastalgia is frequently observed in women suffering 
from premenstrual syndrome,23 but only rarely observed after 
menopause.24 Additionally, patients suffering from breast pain 
have been found to have disorders of lipid metabolism that may 
affect cell wall constitution, locally enhancing cells’ respon-
siveness to endocrine stimulation in a significant manner.25,26 
Accordingly, some studies have been undertaken in order to 
investigate whether women suffering from mastalgia could 
benefit from interventions targeting lipid metabolism.27,28
Myoinositol, a sixfold alcohol of cyclohexane, has been 
proven in separate studies to modulate inflammatory, metabolic, 
oxidative, and endocrine processes in a wide array of human 
diseases, including cancer.29–32 Similarly, both boswellic acid 
and betaine (three-methyl glycine) inhibit inflammation and 
exert protective effects on breast physiology.33–36 Given that 
some reports have documented anecdotal improvement of mas-
talgia in women suffering from polycystic ovary syndrome37 or 
premenstrual dysphoric syndrome38 after treatment with myo-
inositol, we hypothesized that a combination including boswellic 
acid, betaine, and myoinositol would be beneficial in relieving 
breast pain via a multitargeted effect on different pathways, 
including inflammatory, metabolic, and endocrine processes.
Patients and Methods
Patients. Between February 2014 and November 2015, 
76 premenopausal women, aged 22–51 years, were enrolled and 
randomized to receive either a placebo (represented by a mix of 
B vitamins and N-acetylcysteine) or an experimental composi-
tion including boswellic acid, betaine, myoinositol, and vitamins 
belonging to the B group (B2, B6, folic acid, or vitamin B9) in 
association with N-acetylcysteine. Vitamins and the pharma-
cological formula (Eumastós®) were kindly supplied by Lo.Li.
Pharma srl. Capsules in both arms were designed to have an iden-
tical appearance (Table 1). The study protocol was approved by 
the Italian Society of Phytotherapy and Dietary Supplements in 
Obstetrics and Gynecology. Subjects gave their written, informed 
consent to participate in the research, which was conducted in 
accordance with the principles of the Declaration of Helsinki.
Eligibility criteria included: (1) cyclic (for no less than 
7 days during the luteal phase) or noncyclic mastalgia, rang-
ing from mild to severe, for .6 months; (2) premenopausal 
state; and (3) no previous treatment for breast pain during the 
past 4 months prior to the trial. Patients with breast nodules, 
as required by usual best practice, were submitted to the triple 
test with palpation, mammography (often in conjunction with 
ultrasonography), and biopsy.39 Patients affected by breast 
cancer, atypical lobular hyperplasia or sclerosing adenosis 
(two recognized preneoplastic breast pathologies),40 or other 
diseases, such as anemia or metabolic disorders, were excluded. 
Age, weight, and clinical data (breast pain, other symptoms, 
and benign breast nodules) were recorded for each patient and 
are reported in Table 2. Patients under endocrine treatment 
or using hormonal contraceptives were excluded in order to 
avoid potential interferences. Mild changes in menstrual cycle 
rhythm were observed in nearly 50% of patients, but in no 
cases were clinical signs suggesting climacteric onset observed.
To investigate the therapeutic benefit of the experi-
mental treatment, we used a double-blind, randomized, 
placebo-controlled, parallel group design according to a block 
randomization model, described elsewhere.41 In order to ensure 
a correct balance between the two groups, patients were ran-
domized to treatment using a minimization procedure.42 The 
patients of the first group (placebo) received oral capsules (two 
capsules twice a day), containing a combination of vitamins 
(B2, B6, folic acid, and N-acetylcysteine). The patients of the 
second group (treated) received oral capsules (two capsules 
twice a day), filled with the same vitamins plus boswellic acid, 
betaine, and myoinositol.
The first visit to the outpatient clinic included a detailed 
history and a clinical examination by an experienced surgeon. 
Mammography and ultrasound examinations were performed 
at the baseline and after the treatment period (.6 months). 
Table 1. drug formula.
COMPONENT (mg) PLACEBO GROUP EXPERIMENTAL GROUP
Myoinositol – 200
Boswellia – 50
Betaine – 175
Vitamin B6 2.1 2.1
Folic acid 0.3 0.3
Vitamin B2 2.1 2.1
Vitamin B12 0.003 0.003
N-acetylcysteine 100 100
dosage 2 cps twice a day 2 cps twice a day
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Clinical assessment of BBDs (fibroadenoma, duct ectasia, 
and isolated duct papilloma) was obtained by a twice-distinct 
opinion carried out by two expert radiologists. Suspect lesions 
were further evaluated by means of magnetic resonance 
and/or biopsy. Patients suffering from bloody nipple discharge, 
those affected by premalignant lesions (carcinoma in situ), and 
those with breast cancer were excluded. Changes in benign 
breast nodules’ response were considered significant for major 
diameter increase or reduction higher than 20% of their initial 
value measured by mammography. Qualitative assessment of 
breast density was performed according to the study by Oza 
and Boyd,43 subdividing the patients into four main categories 
as follows: (1) almost entirely fat, (2) scattered fibroglandular 
densities, (3) heterogeneously dense, and (4) extremely dense.
Patients were requested not to change their diet during 
the participation in the trial. Patients were seen at baseline (first 
visit), at randomization, and three and six months after random-
ization; the treatment was given for six months. The patient’s 
opinion about the changes in breast complaints was assessed by a 
questionnaire at the time of randomization and again after three 
and six months. Patients were also asked to register the daily 
occurrence of other symptoms (nausea, headache, mood distur-
bances, and menstrual discomfort) and the changes in breast 
tenderness and pain. Pain changes, which were relative to pain 
levels at the time of the previous questionnaire, were scored as -1 
(worsening), 0 (no change), 1 (a little better, with residual, mild 
pain), and 2 (far better, disappearance of breast pain), according 
to a modified Cardiff Breast Score. Overall response rate was 
evaluated after six months by comparing the incidence of respon-
sive patients among the two treatment groups. Pain severity was 
evaluated by patients themselves by means of a 10 cm visual ana-
log scale4 as mild (from 1 to 4 cm), intermediate (from 5 to 7 cm), 
and severe (from 8 to 10 cm). Changes in breast density and nod-
ule dimension were obtained by mammography, performed at 
the beginning of the trial and again after six months.
Statistics. The main outcome of the study was the 
pain relief, while breast lumps and density reduction were 
Table 2. Baseline characteristics of all premenopausal randomized 
patients.
CLINICAL DATA PLACEBO 
GROUP
EXPERIMENTAL 
GROUP
no. of patients 30 32
age (mean, years) (sd) 39.1 (5.8) 38.7 (6.1)
Weight (mean, kg) (sd) 66.7 (5.6) 67.0 (3.4)
Pattern of breast pain
Cyclic 18/30 (60%) 19/32 (59%)
noncyclic 12/30 (40%) 13/32 (41%)
Musculoskeletal ache 7/30 (23,3%) 7/32 (21,8%)
Benign breast nodule 25/30 (83%) 27/32 (84%)
Fibroadenoma 18/30 (60%) 18/32 (56%)
Cyst 12/30 (40%) 14/32 (34%)
high breast density 22/30 (73%) 25/32 (78%)
Menstrual irregularities 7/30 (23%) 8/32 (25%)
Previous treatment 19/30 (63%) 22/32 (68%)
Other symptoms
nausea 2/30 2/32
headache 2/30 3/32
Menstrual pain/discomfort 8/30 10/32
nipple discharge – 1/32
anxiety 12/30 15/32
 
Table 3. Clinical response—pain relief (descriptive data).
SCORE -1 0 1 2 OVERALL RESPONSE (1 + 2)
Placebo group 3/18 12/18 2/18 1/18 3/18
Cyclic pain 16.6% 66.7% 11.1% 5.5% 16.6%
Placebo group 2/12 8/12 2/12 0/12 2/12
noncyclic pain 16.6% 66.7% 16.6% 16.6%
Placebo group 2/7 4/7 1/7 0/7 1/7
Musculoskeletal ache 28,8% 57% 14.2% 14.2%
GlOBal 5/30 20/30 4/30 1/30 5/30
(Cyclic + noncyclic) 16.6% 66.7% 13.3% 3.3% 16.6%
experimental group 2/19 7/19 3/19 7/19 10/19
Cyclic pain 10.5% 36.8% 15.8% 36.8% 52.6%
experimental group 2/13 3/13 6/13 2/13 8/13
noncyclic pain 15.4% 23% 46.1% 15.4% 61.5%
experimental group 1/7 3/7 3/7 0/7 3/7
Musculoskeletal ache 14.2% 42.9% 42.9% 42.9%
GlOBal 4/32 10/32 9/32 9/32 18/32
(Cyclic + noncyclic) 12.5% 31.2% 28.1% 28.1% 56.2%
Pasta et al
40 Breast CanCer: BasiC and CliniCal researCh 2016:10
considered secondary end points important as proof of con-
cept of the therapeutic action. Table 3 reports the distribution 
of the patients pertaining to different study groups (placebo, 
treatment) and type of pain (cyclic, noncyclic), across all the 
four classes of modified Cardiff Breast Score. The term muscle 
ache was an ancillary specification relative to some women of 
both cyclic and noncyclic groups. Inferential statistics (Table 4) 
were based upon the coalescence of scores -1 and 0 into a No ame-
lioration class and scores of 1 and 2 into an Amelioration class.
The scarcity of patients constrained us to adopt the Fisher’s 
exact test for assessing significance instead of chi-square (cells 
with ,5 units). For each pain class and for the whole data 
set, in addition to Fisher’s exact test significance, a confidence 
interval (CI) at 95% of the odds ratio is reported. The CI was 
estimated by means of Wald’s approximation.
Results
Overall, 62 patients completed the trial, while four patients 
were lost during the follow-up for nonmedical reasons; two of 
them, however, reported a significant symptomatic improve-
ment when asked during a telephone interview.
Taken as a whole, the compliance of the two groups was 
higher than expected (93% in the control group and 96% in 
the experimental arm), as the treatment was discontinued only 
in a few cases and for less than a few days.
Pain Relief
Cyclic pain. Among the patients suffering from cyclic 
breast pain within the control group, only 3 of 18 (16.6%) patients 
showed a significant clinical response (Table 3). In the experi-
mental arm, 10 of 19 (56.2%) patients reported significantly 
benefiting from the treatment (P , 0.001, Table 4). In the latter 
group, 7 of 19 (36.8%) patients showed an almost complete dis-
appearance of breast pain at the end of the clinical trial.
Noncyclic pain. A mild improvement in pain relief was 
observed in the control group (2/12, 16.6%), whereas 8 of 
13 women (61.5%) in the experimental arm experienced sig-
nificant pain relief.
Relief of associated musculoskeletal pain was incon-
sistent within the control group, while a mild improvement 
was observed in three of seven patients (42.8%) in the 
experimental arm.
Overall, a significant benefit was observed in 18 of 
32 patients (56.2%) in the experimental arm, while a clinical 
response was documented in a small fraction of the control 
group (5/30, 16.7%). Significant pain relief was observed in 
the experimental group even after the first three months of 
treatment (data not shown).
Other Symptoms
A significant improvement in anxiety-related symptoms was 
observed in both groups, demonstrating that such a benefit 
may derive mostly from the psychological impact of the medi-
cal follow-up (Table 5). Additionally, as anxiety disappears in 
patients who experienced significant pain relief, it is logical 
to speculate that mood change is tightly linked to mastalgia 
improvement. Cyclic breast pain and tenderness are part of 
premenstrual syndrome and are among the constellation of 
physical symptoms associated with premenstrual dysphoric 
disorder. As myoinositol has been shown to significantly ame-
liorate premenstrual syndrome,38 we expected to observe a 
relevant benefit in women who had both premenopausal dis-
turbances and breast pain. Indeed, a significant improvement 
in menstrual discomfort was observed in the experimental 
group, thus giving support to the hypothesis that the experi-
mental drug’s composition in some way modulates endocrine 
responsiveness in premenopausal women.
Benign Breast Lumps and Breast Density
Incidence rates of benign breast nodules were 83% and 84% in 
the placebo and experimental arms, respectively. Mostly, these 
lumps were identified as fibroadenomas (18/30 and 18/32 in 
the control and experimental groups, respectively). The pres-
ence of a single cyst was observed in the remaining patients. 
Dimensions ranged from 0.4 to 0.9  cm for fibroadenomas 
(mean: 0.6 ± 0.2 cm in the control group and 0.5 ± 0.2 cm 
in the experimental arm) and from 0.3 to 1  cm for cysts 
Table 4. Pain relief (drug vs. placebo comparison).
PAIN CLASS OR (95% CONFIDENCE INTERVAL) P-VALUE
Cyclic 1.20 , 5.56 , 25.71 0.025
noncyclic 1.21 , 8 , 52.69 0.029
Muscle-skeletal 0.337 , 4.5 , 60.15 0.28
Global 1.72 , 6.43 , 25.37 0.002
Notes: the inferential statistics rely upon 2 × 2 tables merging -1 and 0 
scores into a no response category and +1 and +2 scores into a response 
category. Global class merges all the three pain classes. Or (odds ratio; Ci) 
values bolded, statistically significant values in italics; P-values are estimated 
by Fisher’s exact test.
Table 5. Other symptoms—relief recorded in the control and experimental groups.
SYMPTOM ANXIETY MENSTRUAL PAIN NIPPLE DISCHARGE HEADACHE NAUSEA
Placebo group
8/12 1/10
– 1/2 1/2
66.7% 10%
experimental group
13/15 8/10
1/1 2/3 2/2
86.7% 80%
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(mean: 0.7 ± 0.3 cm in the control group and 0.7 ± 0.4 cm in 
the experimental arm).
Patients with radiologically and histologically con-
firmed benign breast mass in no case showed signs of wors-
ening (ie, increase in dimension). A significant percentage 
(40%) of women within the experimental group showed a 
reduction in mass dimension after six months of treatment. 
Reduction was considered appreciable for values .20% of the 
initial maximum diameter (Table 6). As expected for young 
women, mammary tissue density was increased in a relevant 
proportion of cases. In the control group, 22/30 patients 
showed grade four breast density (extremely dense), and 25/32 
women in the experimental group had extremely dense breast 
tissue. At the end of the trial, although no appreciable dif-
ferences were found in the placebo group, an unexpected and 
significant decrease in breast density was recorded by mam-
mography among the patients in the experimental arm. Of the 
25 patients who initially showed high density in the experi-
mental group, 60% (15) experienced a significant reduction 
in density over the course of the trial. It is worth noting that 
among these 15 patients, the reduction in tissue compactness 
was also associated with a significant pain reduction for 13 
of the 15 patients. Breast density reduction was significantly 
more marked in the experimental arm (P , 0.001, Table 6). 
Even if the Boyd’s methodology limits us solely to a qualitative 
assessment on density, these results deserve further and more 
detailed investigation. Such a study is currently ongoing.
Adverse Effects
Overall, no significant adverse effects were recorded in either 
arm. One case in the experimental arm experienced transient 
mild diarrhea.
Discussion
Data presented herein suggest that young women suffering 
from mastalgia and showing high breast density experience a 
significant clinical benefit when treated with a balanced com-
position, including boswellic acid, betaine, and myoinositol. 
Pain relief was achieved in a relevant proportion of patients 
enrolled in the experimental arm, and differences in response 
rate between the control and experimental groups have been 
shown to be very significant. It is worth noting that a con-
siderable percentage of women in the experimental group 
experienced a major reduction in breast density. Increased 
breast density is deemed a pivotal risk factor for breast cancer,44 
because it induces high tissue stiffness and an augmented 
remodeling rate. Therefore, reducing mammary compactness 
by means of a simple, natural remedy could bring about very 
relevant clinical outcomes.45
There is considerable debate about the choice of the 
best agent for initial management of mastalgia and BBDs.46 
Although hormonal-based treatments have provided consis-
tent benefits in a large proportion of patients, these drugs are 
difficult to handle for a prolonged period. Concern over the 
long-term safety of tamoxifen still remains, and the incidence 
of side effects with danazol and bromocriptine (ranging from 
30% to 46% according to different reports) leads many women 
to discontinue the therapy. It is generally agreed that hor-
monally active medications are more effective for patients 
with cyclic mastalgia and are indicated only for patients with 
severe, prolonged symptoms.47,48
Some studies have shown obesity and a high fat diet 
to be risk factors involved in the etiology of mastalgia. For 
this reason, other approaches include diet and nutritional 
interventions.46–48 However, there is a lack of direct evidence 
to support this theory, and, to date, no clear-cut consensus 
exists about a better treatment strategy in premenopausal 
mastalgia. Consequently, the search for more manageable 
and safer treatment options has prompted many clinicians to 
investigate different alternatives.49,50
Several vitamins have been evaluated as pharmacological 
support in the management of breast pain. Among many 
formulations, those including vitamin B1, vitamin B6, and 
vitamin E have yielded some results. Namely, early studies 
have evidenced a potential beneficial effect of vitamin E 
(α-tocopherol) in improving breast pain in women with 
fibrocystic breast disease.51,52 Tocopherol is thought to exert 
its effects by modulating steroidal hormone production, cor-
recting abnormal serum cholesterol–lipoprotein distribution, 
and downregulating reactive oxygen species.53 However, these 
preliminary results have not been confirmed by randomized, 
double-blind studies comparing vitamin E with a simple 
placebo.54 To date, even if the evidence supporting routine use 
of vitamins in the management of breast pain is inadequate, 
vitamin supplementation is still regularly recommended by 
general practitioners.55
Table 6. Benign breast lumps and density reduction.
PLACEBO 
GROUP
EXPERIMENTAL 
GROUP
OR (95% CONFIDENCE 
INTERVAL)
P-VALUE
reduction in benign breast lumps
4/25 11/27
0.83 , 3.61 , 16.75 0.07
16% 40.7%
reduction in breast density
2/22 15/25
2.46 , 15 , 118.3 0.001
9.1% 60%
Notes: OR (odds ratio; CI) values bolded, statistically significant values in italics; P-values are estimated by Fisher’s exact test.
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Hypothesizing a synergy among three natural active 
compounds, boswellic acid, betaine, and myoinositol, all of 
which have anti-inflammatory and endocrine-modulating 
properties, we have studied their combined effectiveness in a 
pilot, randomized trial.
Preliminary data presented here support the starting 
assumptions, evidencing that vitamin supplementation, even 
if associated with a well-known antioxidant like acetylcys-
teine, bestows only a minor advantage in ameliorating mas-
talgia. On the contrary, the combination of boswellic acid, 
betaine, and myoinositol significantly improves breast pain 
and reduces mammary density in a relevant percentage of 
patients, without significant side effects. Additionally, the 
experimental formula ameliorates other mastalgia-associated 
symptoms, including anxiety and menstrual discomfort.
This effect is likely to be ascribed to the pleiotropic mech-
anism of action exerted by myoinositol on several metabolic, 
inflammatory, and endocrine pathways. Myoinositol has been 
shown to prevent pulmonary fibrosis after asbestos or inflam-
matory injury56 and inhibit chronic colon inflammation,29 
likely by modulating the redox balance.57 In addition, myo-
inositol may contrast inflammation-induced fibrosis by mod-
ulating TGF-β activity. TGF-β, particularly the TGF-β1 
isoform, is a potent profibrogenic agent inducing collagen syn-
thesis and regulating the balance between matrix-degrading 
metalloproteinases and their inhibitors.58 In this way, it is a 
prominent factor in orchestrating cross-talk among epithelial 
cells and their microenvironment.59 Myoinositol significantly 
modulates the expression of genes encoding TGF-βs and their 
receptors, thereby exerting immune-regulatory effects on the 
colonic epithelium under inflammatory conditions or during 
microbe-induced infection/inflammation in order to maintain 
the colonic mucosa in a noninflammatory state or to coun-
teract infection.60,61 Breast fibrosis is usually recorded as an 
increase of breast density during mammographic examination 
and is likely to contribute to both mammary tenderness and 
pain. Given that TGF-β deregulation has been observed in 
BBDs,62 modulation of TGF-β with myoinositol may signifi-
cantly inhibit some clinical consequences, such as mastalgia. 
In addition, myoinositol exerts a modulating activity on cell 
metabolism, by improving glucose uptake and normalizing 
lipid metabolism.63 Deregulated lipid metabolism partici-
pates in some way in the pathogenesis of BBDs: low levels 
of gamma-linolenic acid metabolites, as well as changes in 
serum lipoprotein patterns, may affect breast sensitivity to 
prolactin or to estrogens via prostaglandins and other signal-
ing pathways.64,65 Therefore, it could be hypothesized that 
myoinositol may improve the clinicopathological features of 
both mastodynia and breast compactness by interfering with 
tissue metabolism at local and systemic levels. In fact, as 
demonstrated by a compelling body of scientific data, myo-
inositol improves altered metabolic and hormonal patterns in 
polycystic ovary syndrome (PCOS) patients.66,67 Myoinositol 
restores insulin sensitivity, counteracts hyperandrogenism, 
and modulates estrogen and follicle-stimulating hormone 
(FSH) activity in the ovaries.68,69 It is therefore likely that 
such a regulatory effect would be displayed in women affected 
by mastalgia and BBDs who were treated with myoinositol.
Conclusions
Women suffering from mastalgia and showing high breast 
density experience a significant clinical benefit when treated 
with a balanced composition, including boswellic acid, beta-
ine, and myoinositol. However, studies on the clinical man-
agement of BBDs are frequently biased by statistical or design 
inadequacy, thus leading to untrustworthy conclusions.46 
Undoubtedly, our pilot study suffers from limitations and 
our main findings should be confirmed by a large survey, 
which should evaluate the length of the clinical response and 
any significant relapse rate. That study is currently ongoing. 
Nevertheless, data reported herein have demonstrated that 
the use of these natural combinations could be an important 
alternative therapy to current drugs for the management of 
benign breast disorders without side effects. Indeed, the pro-
posed treatment offers a high response rate, thus making it a 
reliable option for prolonged treatment.
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